New York – March 30, 2017 – Cooley advised Cara Therapeutics on its $80 million follow-on offering of 4,450,000 common shares. The underwriters have a 30-day option to purchase up to 667,500 additional shares.
Cara, which trades on The NASDAQ Global Market as “CARA,” is a clinical-stage biotech company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors.
In 2014, Cooley advised Cara on its $55 million IPO.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.